E. Apetrei *, Mihaela Rugină *
Prof. Dr. Eduard Apetrei, Dr. Mihaela Rugină – Institutul de Cordiologie Prof. C.C. Iliescu
Abstract
A multicentric study, that took place in 16 cardiological clinics all over the country, is presented. The study was performed on a number of 354 patients with mild and moderate essential hypertension and its purpose was the ambulatory evaluation of the antihypertensive effectiveness of Nebivolol (Nebilet®). The patients were monitored for an 8-weeks period, using a single dose per day (2,5-10 mg, depending on the response). 68% of the patients took only Nebilet® (monotherapy), whereas 32°70 needed an association with another antihypertensive drugs (diuretics, ACE inhibitors). Nebivolol (Nebilet®) prescribed in a single dose per day induces a decrease in both diastolic and systolic blood pressure. The diastolic blood pressure decreases -below 90 mm Hg in over 90% of the patients, as well as the systolic one, which decreases below 140 mm Hg in over 65°/0 of the patients. Nebivolol had no influence on the lipid or carbohydrates metabolism and the adverse events noticed were of no importance.